Briefs

GeneTrace Systems Inc. and Molecular Mining Corporation have announced
that they will collaborate to design, analyze, define and validate a
physiological network model for application to drug discovery. The two
companies will co-fund research and share revenues generated by any
findings that arise out of the joint program. The collaboration will
employ the companies' shared strategy of using systems biology to
elucidate complex gene interactions in a human physiological network
with the goal of discovering novel targets and strategies for compound
lead generation.

GeneTrace will contribute its broad high throughput systems biology
platform to measure a variety of parameters across the cell from DNA
to RNA to protein to phenotype for a particular physiological
system. Molecular Mining will apply its innovative data mining and
modeling capability to establish the network model based on the
experimental data generated. George B. LaMotte, III, Ph.D., GeneTrace
CEO commented, "This collaboration represents a realization of our
strategy to use systems biology to truly elucidate the complex gene
interactions responsible for the development of complex diseases such
as cancer, cardiovascular disease and metabolic disorders. We are
fortunate to partner with Molecular Mining, a champion of the network
approach to target discovery who represents the vanguard in superior
data mining and network modeling capabilities."

"We're very excited about this collaborative project, said Evan Steeg,
Ph.D., CEO of Molecular Mining Corporation. "It's an important step in
our strategy of demonstrating the biomedical utility and commercial
value of gene networks and of our advanced data mining and modeling
platform. GeneTrace's ability to efficiently generate high throughput,
high precision expression and molecular perturbation data makes them
an ideal partner for us." Roland Somogyi, Ph.D., CSO, added, "This
collaboration represents a major step forward in delivering on the
promise of post-genomics: elucidating networks of complex gene
interactions and discovering novel gene function. The project's
strength lies in the unique combination of GTS and MMC technologies
for systematic experimental design, network reverse engineering,
hypothesis generation, and validation. We aim to provide a
revolutionary platform for dependable in silico experimentation. The
resulting network model is expected to enable breakthrough discoveries
and provide major increases in therapeutic research efficiency."

GeneTrace is a biomedical company focused on the delivery of superior
therapeutic drug targets and well-characterized small molecule
leads. GeneTrace exploits its broad, proprietary platform to find
patterns of dynamic interaction between genes and gene products that
underlie disease. The Company utilizes its biology and bioinformatics
engines to determine drug mechanisms of action, validate potential
drug targets and select drug candidates based on patterns of gene
interactions and toxicogenomics. GeneTrace believes that their Systems
Biology approach will shorten the time to bring a candidate to the
clinic and increase its chances of reaching the market.

Molecular Mining Corporation is a life sciences data mining company
and a leader in the advanced computational methods necessary for
identification of complex molecular interactions. The company is well
positioned to take advantage of the data being generated by high
throughput molecular assays, ultimately providing the gene network
models for in silico target identification, drug screening and
predictive medicine.

CONTACT: Maria Straatmann, Business Development of GeneTrace Systems,
Inc., 510-748-6157, or fax, 510-748-6145, or straatmann@genetrace.com;
or Sally Rigden, Ph.D., Manager, Operations of Molecular Mining Corp.,
613-547-9752, ext. 229, or fax, 613-547-6835, or
srigden@molecularmining.com.

SOURCE GeneTrace Systems, Inc www.genetrace.com